Skip to main content
SpringerLink
Log in

Guidelines for the Rational Use of Benzodiazepines

When and What to Use

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The main actions of benzodiazepines (hypnotic, anxiolytic, anticonvulsant, myorelaxant and amnesic) confer a therapeutic value in a wide range of conditions. Rational use requires consideration of the large differences in potency and elimination rates between different benzodiazepines, as well as the requirements of individual patients.

As hypnotics, benzodiazepines are mainly indicated for transient or short term insomnia, for which prescriptions should if possible be limited to a few days, occasional or intermittent use, or courses not exceeding 2 weeks. Temazepam, loprazolam and lormetazepam, which have a medium duration of action are suitable. Diazepam is also effective in single or intermittent dosage. Potent, short-acting benzodiazepines such as triazolam appear to carry greater risks of adverse effects.

As anxiolytics, benzodiazepines should generally be used in conjunction with other measures (psychological treatments, antidepressants, other drugs) although such measures have a slower onset of action. Indications for benzodiazepines include acute stress reactions, episodic anxiety, fluctuations in generalised anxiety, and as initial treatment for severe panic and agoraphobia. Diazepam is usually the drug of choice, given in single doses, very short (1 to 7 days) or short (2 to 4 weeks) courses, and only rarely for longer term treatment. Alprazolam has been widely used, particularly in the US, but is not recommended in the UK, especially for long term use.

Benzodiazepines also have uses in epilepsy (diazepam, clonazepam, clobazam), anaesthesia (midazolam), some motor disorders and occasionally in acute psychoses.

The major clinical advantages of benzodiazepines are high efficacy, rapid onset of action and low toxicity. Adverse effects include psychomotor impairment, especially in the elderly, and occasionally paradoxical excitement. With long term use, tolerance, dependence and withdrawal effects can become major disadvantages. Unwanted effects can largely be prevented by keeping dosages minimal and courses short (ideally 4 weeks maximum), and by careful patient selection. Long term prescription is occasionally required for certain patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marriott S, Tyrer P. Benzodiazepine dependence: avoidance and withdrawal. Drug Saf 1993; 9: 93–103

    Article  PubMed  CAS  Google Scholar 

  2. Committee on Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Curr Probl 1988; 21

  3. Royal College of Psychiatrists. Benzodiazepines and dependence: a college statement. Bull Royal College Psychiatrists 1988; 12: 107–8

    Article  Google Scholar 

  4. The treatment of insomnia. [editorial]. Drug Ther Bull 1990; 28: 97–9

  5. Taylor D. Current usage of benzodiazepines in Britain. In: Freeman H, Rue Y, editors. The benzodiazepines in current clinical practice. London: Royal Society of Medicine Services, 1987: 13–8

    Google Scholar 

  6. Swift CG, Shapiro CM. Sleep and sleep problems in elderly people. BMJ 1993; 306: 1468–71

    Article  PubMed  CAS  Google Scholar 

  7. Crook TH, Kupfer DJ, Hoch CC, et al. Treatment of sleep disorders in the elderly. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1159–65

    Google Scholar 

  8. Beaumont G. The use of benzodiazepines in general practice. In: Hindmarch I, Beaumont G, Brandon S, Leonard BE, editors. Benzodiazepines: current concepts. Chichester: John Wiley & Sons, 1990: 141–52

    Google Scholar 

  9. Espie CA. Practical management of insomnia: behavioural and cognitive techniques. BMJ 1993; 306: 509–11

    Article  PubMed  CAS  Google Scholar 

  10. Marks J, Nicholson AN. Drugs and insomnia. BMJ 1984; 288: 261

    Article  PubMed  CAS  Google Scholar 

  11. Hartman E. Long term administration of psychotropic drugs: Effects on human sleep. In: Williams RI, Karacan I, editors. Pharmacology of sleep. New York: John Wiley & Sons Inc, 1976: 211–4

    Google Scholar 

  12. Kay DC, Blackburn AB, Buckingham JA, Karacan I. Human pharmacology of sleep. In: Williams RL, Karacan I, editors. Pharmacology of sleep, New York: John Wiley & Sons Inc., 1976: 83–210

    Google Scholar 

  13. Wheatley D. Effects of drugs on sleep. In: Wheatley D, editor. Psychopharmacology of sleep. New York: Raven Press, 1981: 153–76

    Google Scholar 

  14. Schneider-Helmert D. Overestimations of hypnotic drug effects by insomniacs — a hypothesis. Psychopharmacology 1985; 87: 107–10

    Article  PubMed  CAS  Google Scholar 

  15. Petursson H, Lader MH. Benzodiazepine dependence. Br J Addict 1984; 76: 133–45

    Article  Google Scholar 

  16. Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. Science 1978; 201: 1039–41

    Article  PubMed  CAS  Google Scholar 

  17. Adam K, Adamson L, Brezinova V, et al. Nitrazepam: Lastingly effective but trouble on withdrawal. BMJ 1976; 1: 1558–62

    Article  PubMed  CAS  Google Scholar 

  18. Kales A, Soldatos CR, Bixler EO, et al. Diazepam: effects on sleep and withdrawal phenomena. J Clin Psychopharmacol 1988; 8: 340–6

    Article  PubMed  CAS  Google Scholar 

  19. Oswald I, French C, Adam K, et al. Benzodiazepine hypnotics remain effective for 24 weeks. BMJ 1982; 2: 860–3

    Article  Google Scholar 

  20. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 1986; 88; 426–33

    Article  PubMed  CAS  Google Scholar 

  21. Lader M. Long-term benzodiazepine use and psychological functioning. In: Freeman H, Rue Y, editors. The benzodiazepines in current clinical practice. International Congress and Symposium Series, Royal Society of Medicine Services, London and New York, 1987: 55–69

  22. Nicholson AN. Hypnotics: rebound insomnia and residual sequelae. Br J Clin Pharmacol 1980; 9: 223–5

    Article  PubMed  CAS  Google Scholar 

  23. Nicholson AN. The use of short and long-acting hypnotics in clinical medicine. Br J Clin Pharmacol 1980; 11 Suppl. 1: 61–9

    Google Scholar 

  24. Tyrer P. Withdrawal from hypnotic drugs. BMJ 1993; 306: 706–8

    Article  PubMed  CAS  Google Scholar 

  25. Morgan K, Oswald I. Anxiety caused by a short-life hypnotic. BMJ 1982; 284: 942

    Article  PubMed  CAS  Google Scholar 

  26. Bixler EO, Kales A, Manfredi RL, et al. Next day memory impairment with triazolam use. Lancet 1991; 337: 827–31

    Article  PubMed  CAS  Google Scholar 

  27. Bond A, Lader M. After-effects of sleeping drugs. In: Wheatley D, editor. Psychopharmacology of sleep. New York: Raven Press, 1981: 177–97

    Google Scholar 

  28. Hindmarch I. Human psychopharmacological differences between benzodiazepines. In: Hindmarch I, Beuamont G, Brandon S, Leonard BE, editors. Benzodiazepines: current concepts. Chichester: John Wiley & Sons, 1990: 73–92

    Google Scholar 

  29. Castleden CH, George GF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. BMJ 1977; 1: 10–2

    Article  PubMed  CAS  Google Scholar 

  30. Dement WC, Mitler MM. Its time to wake up to the importance of sleep disorders. JAMA 1993; 269: 1548–50

    Article  PubMed  CAS  Google Scholar 

  31. Hallstrom C, Lader M. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiat 1981; 16: 235–44

    CAS  Google Scholar 

  32. Owen RT, Tyrer P. Benzodiazepine dependence: a review of the evidence. Drugs 1983; 25: 385–98

    Article  PubMed  CAS  Google Scholar 

  33. Ashton H. Benzodiazepine withdrawal: an unfinished story. BMJ 1984; 288: 1135–40

    Article  PubMed  CAS  Google Scholar 

  34. Cohn MA. Hypnotics and the control of breathing: a review. Br J Clin Pharmacol 1983; 16: 245S–50S

    Article  PubMed  Google Scholar 

  35. Morgan K. Hypnotics in the elderly: what cause for concern?. Drugs 1990; 40: 688–96

    Article  PubMed  CAS  Google Scholar 

  36. Greenblatt DJ, Divoll M, Abernethy DR, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1983; 8: 233–52

    Article  PubMed  CAS  Google Scholar 

  37. Lader M. Avoiding long-term use of benzodiazepine drugs. Prescriber March 1991: 79–83

  38. Mendelson WB. Medications in the treatment of sleep disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1305–11

    Google Scholar 

  39. Dorian P, Sellers EM, Kaplan H, et al. Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 1983; 27 Suppl. 2: P228–34

    Article  Google Scholar 

  40. Committee on Safety of Medicines. Current problems. 1990; 30

  41. Consensus Conference. Guidelines for the management of patients with generalised anxiety. Psychiatric Bull 1992; 16: 560–5

    Article  Google Scholar 

  42. Russell J, Lader M, editors. Guidelines for the prevention and treatment of benzodiazepine dependence. London: Mental Health Foundation, 1993

    Google Scholar 

  43. Uhlenuth EH, Baiter MB, Mellinger GD, et al. Symptom checklist syndromes in the general population. Arch Gen Psychiatry 1983; 40: 1167–73

    Article  Google Scholar 

  44. Hallstrom C. Coping with anxiety: the patient’s predicament. In: Wheatley D, editor. The anxiolytic jungle: where next? Chichester: John Wiley & Sons Ltd., 1990: 99–111

    Google Scholar 

  45. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 3rd. rev., ed. Washington DC: American Psychiatric Association, 1987: 297–313

    Google Scholar 

  46. Tyrer P. Neurosis divisible?. Lancet 1985; 1: 685–8

    Article  PubMed  CAS  Google Scholar 

  47. Tyrer P. Choices of treatment in anxiety. In: Tyrer P, editor. Psychopharmacology of anxiety. Oxford: Oxford Medical Publications, 1989: 255–82

    Google Scholar 

  48. Cloninger CR. Recent advances in the genetics of anxiety and somatoform disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 955–65

    Google Scholar 

  49. Nutt DJ. Anxiety and its therapy: today and tomorrow. In: Briley M, File SE, editors. New Concepts in Anxiety. Basingstoke: Macmillan Press Ltd, 1990: 2–11

    Google Scholar 

  50. Wheatley D. The new alternatives. In: Wheatley D, editor. The anxiolytic jungle: where next? Chichester: John Wiley & Sons, 1990: 163–84

    Google Scholar 

  51. Haefely W, Pieri L, Pole P, et al. General pharmacology and neuropharmacology of benzodiazepine derivatives. In: Hoffmeister H, Stille G, editors. Handbook of experimental pharmacology (Vol. 55, II) Berlin: Springer-Verlag, 1981: 113–62

    Google Scholar 

  52. Committee on Review of Medicines. Systematic review of the benzodiazepines. BMJ 1980; 1: 910–2

    Google Scholar 

  53. Tyrer P. Benefits and risks of benzodiazepines. In: Freeman H, Rue Y, editors. The benzodiazepines in current clinical practice. London: Royal Society of Medicine Services, 1987: 3–12

    Google Scholar 

  54. Rickels K, Case WG, Downing RW, et al. Indications and contraindications for chronic anxiolytic treatment: is there tolerance to the anxiolytic effect? In: Kemali D, Racagni G, editors. Chronic treatments in neuropsychiatry. New York: Raven Press, 1985: 193–204

    Google Scholar 

  55. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987:82:665–71

    Article  PubMed  CAS  Google Scholar 

  56. Kraupl Taylor F. The damnation of benzodiazepines. Br J Psychiatry 1989; 154: 697–704

    Article  Google Scholar 

  57. Lader M. Benzos and memory loss: More than just ‘old age’. Prescriber 1992; 3: 13

    Google Scholar 

  58. McClelland HA. The forensic implications of benzodiazepine usage. In: Hindmarch I, Beaumont G, Brandon S, Leonard BE, editors. Benzodiazepines: current concepts. Chichester: John Wiley & Sons, 1990: 227–50

    Google Scholar 

  59. Gray JA. The neuropsychology of emotion and personality. In: Stahl SM, Iversen SD, Goodman ED, editors. Cognitive neurochemistry. Oxford: Oxford University Press, 1987: 171–90

    Google Scholar 

  60. Lader MH, Petursson H. Benzodiazepine derivatives — side effects and dangers. Biol Psychiatry 1981; 16: 1195–212

    PubMed  CAS  Google Scholar 

  61. Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1998; 49: 184–8

    Google Scholar 

  62. Van Der Bijl P, Roelofse JA. Disinhibitory reactions to benzodiazepines: a review. J Oral Maxillofac Sur 1991; 49: 519–23

    Article  Google Scholar 

  63. Murphy SB, Tyrer P. The essence of benzodiazepine dependence. In: Lader M, editor. The psychopharmacology and addiction. Oxford: Oxford University Press, 1988: 157–67

    Google Scholar 

  64. Tyrer P. Risks of dependence on benzodiazepine drugs: the importance of patient selection. BMJ 1989; 298: 102–5

    Article  PubMed  CAS  Google Scholar 

  65. Herman JB, Brotman AW, Rosenbaum JF. Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. J Clin Psychiatry 1987; 48 Suppl. 10: 22–6

    PubMed  Google Scholar 

  66. Sheehan DV, Coleman JH, Greenblatt DJ, et al. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 1984; 4; 66–75

    Article  PubMed  CAS  Google Scholar 

  67. Sheehan DV. Benzodiazepines in panic disorder and agoraphobia. J Affect Disord 1987; 13: 169–81

    Article  PubMed  CAS  Google Scholar 

  68. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. Arch Gen Psychiatry 1988; 45; 413–22

    Article  PubMed  CAS  Google Scholar 

  69. Noyes R, DuPont RL, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: II. Patient acceptance, side effects and safety. Arch Gen Psychiatry 1988; 45: 423–8

    Article  PubMed  Google Scholar 

  70. Tesar GE. High-potency benzodiazepines for short-term management of panic disorder: the US experience. J Clin Psychiatry 1990; 51: 4–10

    PubMed  Google Scholar 

  71. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry 1988; 45: 429–36

    Article  PubMed  CAS  Google Scholar 

  72. Pollack MH. Long-term management of panic disorder. J Clin Psychiatry 1990; 51: 11–3

    PubMed  Google Scholar 

  73. Marks IM, o’sullivan G. Anti-anxiety drug and psychological treatment effects in agoraphobia/panic and obsessive-compulsive disorders. In: Tyrer P, editor. Psychopharmacology of anxiety. Oxford: Oxford University Press, 1989: 196–242

    Google Scholar 

  74. Rizley R, Kahn RJ, McNair DM, et al. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull 1986; 22; 167–72

    PubMed  CAS  Google Scholar 

  75. Nutt DJ, Glue P. Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. Pharmacol Ther 1989; 44: 309–34

    Article  PubMed  CAS  Google Scholar 

  76. Schweizer E, Clary C, Dever Al, et al. The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. J Clin Psychiatry 1992; 53: 19–22

    PubMed  CAS  Google Scholar 

  77. Feighner JP. Benzodiazepines as antidepressants. In: Ban TA, editor. Modern problems of pharmacopsychiatry. Basel: S Karger, 1982: 196–212

    Google Scholar 

  78. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia. I. frequency, severity, and response to treatment. Arch Gen Psychiatry 1988: 45; 437–43

    Article  PubMed  CAS  Google Scholar 

  79. Ashton H, Golding JF. Tranquillisers: prevalence, predictors and possible consequences. Data from a large United Kingdom survey. Br J Addict 1989; 84: 541–6

    CAS  Google Scholar 

  80. Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 1991; 8; 19–28

    Article  PubMed  CAS  Google Scholar 

  81. Holton A, Tyrer P. Five year outcome in patients withdrawn from long term treatment with diazepam. BMJ 1990; 300: 1241–2

    Article  PubMed  CAS  Google Scholar 

  82. Rickels K, Schweizer E, Case WG. Withdrawal problems with anti-anxiety drugs: nature and management. In: Tyrer P, editor. Psychopharmacology of anxiety. Oxford: Oxford University Press, 1989: 283–94

    Google Scholar 

  83. Brodie MJ. Status epilepticus in adults. BMJ 1990; 336: 551–2

    CAS  Google Scholar 

  84. Trimble MR. Benzodiazepines in clinical practice. In: Wheatley D, editor. The anxiolytic jungle: where next? Chichester: John Wiley & Sons, 1990:9–21

    Google Scholar 

  85. Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. BMJ 1990; 336: 350–4

    CAS  Google Scholar 

  86. Feely M. Clonazepam and clobazam. Prescribes J 1989; 29: 111–5

    Google Scholar 

  87. Dundee JW. The application of the benzodiazepines in anaesthesia. In: Hindmarch I, Beaumont G, Brandon, S, Leonard BE, editors. Benzodiazepines: current concepts. Chichester: John Wiley & Sons Ltd, 1990: 153–68

    Google Scholar 

  88. Herrington RN. The uses of benzodiazepines in neuropsychiatry. In: Hindmarch I, Beuamont G, Brandon S, Leonard BE, editors. Benzodiazepines: Current Concepts. Chichester: John Wiley & Sons Ltd, 1990: 95–110

    Google Scholar 

  89. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714–26

    PubMed  CAS  Google Scholar 

  90. Potokar J, Nutt DJ. Anxiolytic potential of benzodiapepine receptor partial agonists. CNS Drugs 1994; 1: 305–15

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Psychopharmacology Unit, Department of Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, England

    Heather Ashton

Authors
  1. Heather Ashton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ashton, H. Guidelines for the Rational Use of Benzodiazepines. Drugs 48, 25–40 (1994). https://doi.org/10.2165/00003495-199448010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199448010-00004

Keywords

Search

Navigation